Management & Board

  • Rav Mlait, MBA

    CEO, Director

    Mr. Mlait has extensive experience in managing and raising capital for public and private companies in the technology and resource sectors. Mr. Mlait holds an MBA from Royal Roads University in British Columbia with a specialization in Executive Management and his BA (Economics) from Simon Fraser University and has worked with public companies listed on the TSX, TSX Venture exchange and CSE. Mr. Mlait has extensive experience in capital markets, technology start-ups, university technology transfer and business development. 

  • Dr. Raj Attariwala, MD, Ph.D.

    Chief Scientific Officer

    Dr. Attariwala is a Vancouver based dual board certified Radiologist and Nuclear Medicine physician certified in both Canada and the United States. He received his formal medical training at University of British Columbia with periods of specialized medical training at Memorial Sloan Kettering Cancer Centre (New York), UCLA and USC. He holds a doctorate in Biomedical Engineering from Northwestern University (Evanston, IL).  Dr.  Attariwala is a practicing physician in British Columbia and is the owner of AIM medical imaging in Vancouver.  He has pioneered advances in the field of whole body medical imaging through his work and authored numerous publications and presented at international medical conferences on whole body imaging and cancer detection. Dr. Attariwala has worked closely with the breath testing technology leaders and has utilized his educational training and background in biomedical engineering to formulate product design and patent applications for Cannabix.  Dr.  Attariwala also has several other medical device patents under developments in the field of nuclear medicine. Dr. Attariwala is a Founding Radiologist of Prenuvo, a cutting edge MRI scanning technology company for early detection of cancer and other diseases.

  • Dr. Phillip Olla, Ph.D.

    Director

    Dr. Olla is an expert in breath technologies, breathomics, healthcare innovation, artificial and medical informatics. Dr. Olla has served as the CEO of Audacia Bioscience a health informatics company who performed substantial work in cannabis breath research and development. Dr. Olla is an associate professor at University of Detroit Mercy in Michigan and is the Vice Chair of the MedHealth Consortium.

    Dr. Olla's contributions within the digital health arena have been acknowledged internationally and he has been a speaker at the United Nations conference and World Health Organization.   Notably, his professional journey includes collaborations with companies like IBM, Roche Diagnostics and Morgan Stanley. Dr. Olla holds a Ph.D. in Management Information Systems (MIS) from Brunel University, United Kingdom.

  • Bryan Loree BA, CMA

    CFO, Director

    Mr. Loree has held various senior accounting roles for public and private companies in various industries including, renewable energy, exploration, and construction. During this time he has also performed capital raising activities for both private and public companies, primarily in the exploration and renewable energy sectors. Prior to entering the accounting field, Mr. Loree spent three years as an investor relations manager for several public companies and two years in the banking industry. Mr. Loree holds a Certified Management Accountant designation, a Financial Management Diploma from the British Columbia Institute of Technology, and a BA from Simon Fraser University.

  • Dr. Moe Paknahad, Ph.D.

    VP Technology Development

    Dr. Paknahad is an Electrical Engineer who has spent last 10 years on research and development and product development in biomedical and environmental monitoring devices with skills in prototyping, piloting and commercialization. Dr. Paknahad received his PhD in electrical engineering at the University of British Columbia (UBC) an completed his post-doctorate at University of Toronto. He is a specialist in the areas of microfluidics, machine olfaction, sensors, organ-on-chip and lab-on-chip technologies.

  • Thomas Clarke, M.Sc

    Director

    Mr. Clarke is a business entrepreneur holding a BSc. (Honours) and MSc in Geology from the University of the Witwatersrand as well as a BSc in Geography from the University of Lethbridge.

Advisors

  • Dr. Bruce Goldberger, Ph.D.

    Scientific Advisor

    Dr. Goldberger is a professor, and the director of toxicology for the Department of Pathology, Immunology and Laboratory Medicine in the College of Medicine at the University of Florida.  Dr. Goldberger is the editor-in-chief of the Journal of Analytical Toxicology; the president of the American Board of Forensic.

  • Dr. Rick Yost, Ph.D.

    Scientific Advisor

    Dr. Yost, Col. Allen R. & Margaret G. Crow Professor and Head of Analytical Chemistry at the University of Florida. Dr. Yost’s research has involved over 100 graduate students funded by over $40 million in research grants, and has published over 160 papers and 16 patents. Over $30 billion worth of instruments have been sold based on these patents.

  • Dr. Randy Purves, Ph.D.

    Scientific Advisor

    Dr. Purves is one of the world’s foremost experts in the development of FAIMS (high-field asymmetric waveform ion mobility spectrometry) instrumentation and applications. Dr. Purves is a pioneer in developing FAIMS technology and in 2001 he co-founded Ionalytics, an instrument company specializing in FAIMS devices for use with mass spectrometry. Ionalytics was acquired by Thermo Electron (now Thermo Fisher Scientific) in 2005 and Dr. Purves was part of the Thermo team involved with the commercial release of an integrated FAIMS product for use with a TSQ Quantum mass spectrometer in 2006.  Dr. Randy Purves obtained his Ph.D. in Analytical Chemistry from the University of Alberta. Dr. Purves has over 25 years of experience working with mass spectrometry.

  • Rocco Iannapollo

    HR Advisor

    Mr. Iannapollo is an expert on substance abuse programs with more than 20 years of experience in the oil and gas industry, working for fortune 50 companies. Rocco has extensive experience with supplier, employer, and DOT compliance policies and strategies. He also brings deep business acumen regarding operations and supply chain best practices. Mr. Iannapollo is a member of the Substance Abuse Program Administrator’s Association (SAPAA), the Drug and Alcohol Testing Industry Association (DATIA), as well as a speaker and regular contributor to the International Forum for Drug and Alcohol Testing (IFDAT).